These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32229161)

  • 41. Corrigendum to 'Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2' [Cancer Lett. 2016 Dec 28; 383 (2):272-281].
    Tu M; Lu C; Lv N; Wei J; Lu Z; Xi C; Chen J; Guo F; Jiang K; Li Q; Wu J; Song G; Wang S; Gao W; Miao Y
    Cancer Lett; 2019 Mar; 444():189-190. PubMed ID: 30594325
    [No Abstract]   [Full Text] [Related]  

  • 42. Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Yin H; Wang X; Zhang X; Zeng Y; Xu Q; Wang W; Zhou F; Zhou Y
    Cancer Lett; 2022 Sep; 543():215792. PubMed ID: 35718664
    [No Abstract]   [Full Text] [Related]  

  • 43. Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals" [Cancer Lett. 386 (2017) 12-23].
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2018 Feb; 414():310. PubMed ID: 29097156
    [No Abstract]   [Full Text] [Related]  

  • 44. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25].
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2022 Feb; 526():363. PubMed ID: 34872789
    [No Abstract]   [Full Text] [Related]  

  • 45. Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2021 Feb; 499():2. PubMed ID: 32563702
    [No Abstract]   [Full Text] [Related]  

  • 46. Corrigendum to "
    Zhou X; Zhang W; Dou M; Li Z; Liu Z; Li J; Tian C; Yao Y; Wang C; Li Y; Chen P; Han X; Jiao D
    Cancer Lett; 2023 Jul; 567():216282. PubMed ID: 37344309
    [No Abstract]   [Full Text] [Related]  

  • 47. Corrigendum to "Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma" [Canc. Lett. 503 (2021) 43-53].
    Chen S; Yang M; Wang C; Ouyang Y; Chen X; Bai J; Hu Y; Song M; Zhang S; Zhang Q
    Cancer Lett; 2022 Jul; 537():215688. PubMed ID: 35459579
    [No Abstract]   [Full Text] [Related]  

  • 48. Corrigendum to "Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1" [Canc. Lett. 385 (2017) 65-74].
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2022 Aug; 540():215739. PubMed ID: 35599097
    [No Abstract]   [Full Text] [Related]  

  • 49. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner" [Canc. Lett. 371 (2016) 354-365].
    Zheng S; Chen H; Wang Y; Gao W; Fu Z; Zhou Q; Jiang Y; Lin Q; Tan L; Ye H; Zhao X; Luo Y; Li G; Ye L; Liu Y; Li W; Li Z; Chen R
    Cancer Lett; 2022 Oct; 545():215859. PubMed ID: 35940956
    [No Abstract]   [Full Text] [Related]  

  • 50. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
    O'Conor CJ; Chen T; González I; Cao D; Peng Y
    Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
    Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
    J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
    Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
    Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].
    Yuan ZY; Wang SS; Gao Y; Su ZY; Luo WB; Guan ZZ
    Ai Zheng; 2008 Jun; 27(6):561-5. PubMed ID: 18570725
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48].
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2018 May; 422():131. PubMed ID: 29579438
    [No Abstract]   [Full Text] [Related]  

  • 57. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
    Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
    Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.
    Bansal N; Petrie K; Christova R; Chung CY; Leibovitch BA; Howell L; Gil V; Sbirkov Y; Lee E; Wexler J; Ariztia EV; Sharma R; Zhu J; Bernstein E; Zhou MM; Zelent A; Farias E; Waxman S
    Oncotarget; 2015 Oct; 6(33):34087-105. PubMed ID: 26460951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-103 regulates triple negative breast cancer cells migration and invasion through targeting olfactomedin 4.
    Xiong B; Lei X; Zhang L; Fu J
    Biomed Pharmacother; 2017 May; 89():1401-1408. PubMed ID: 28320108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.